Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABP 692 vs Ocrelizumab in Relapsing-remitting Multiple Sclerosis
NCT06700343Phase 3Active, not recruiting
- Sponsor
- Amgen
- Start
- Jan 2025
- Primary completion
- Apr 2027
- Modality
- Monoclonal Antibodies
- Countries
- 22
01
Overview
Phase 3, randomised, double-blind trial of ABP 692 in relapsing-remitting multiple sclerosis (RRMS) (3 arms), sponsored by Amgen. Primary endpoints: Area Under the Serum Concentration-time Curve From Time 0 to Day 15 and Area Under the Serum Concentration-time Curve From Time 0 Extrapolated to Infinity at 16 weeks. Started Jan 2025; status: active, not recruiting.
02
Drugs
ABP 692
03
Conditions
relapsing-remitting multiple sclerosis (RRMS)
Beyond the preview
Go deeper on NCT06700343.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06700343.